ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
The cardiotoxic effects of doxorubicin, a potent chemotherapeutic agent, have been linked to DNA damage, oxidative mitochondrial damage, and nuclear translocation of p53, but the exact molecular mechanisms causing p53 transactivation and doxorubicin-induced cardiomyopathy are not clear. The present study was carried out to determine whether extracellular signal-regulated kinases (ERKs), which are known to be activated by DNA damaging agents, are responsible for doxorubicin-induced p53 activation and oxidative mitochondrial damage in H9c2 cells. Cell death was measured by terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling, annexin V-fluorescein isothiocyanate, activation of caspase-9 and -3, and cleavage of poly(ADP-ribose) polymerase (PARP). We found that doxorubicin produced cell death in H9c2 cells in a time-dependent manner, beginning at 6 h, and these changes are associated decreased expression of Bcl-2, increases in Bax and p53 upregulated modulator of apoptosis-α expression, and collapse of mitochondria membrane potential. The changes in cell death and Bcl-2 family proteins, however, were preceded by earlier activation and nuclear translocation of ERKs, followed by increased phosphorylation at Ser15 and nuclear translocation of the phosphorylated p53. The functional importance of ERK1/2 and p53 in doxorubicin-induced toxicity was further demonstrated by the specific ERK inhibitor U-0126 and p53 inhibitor pifithrin (PFT)-α, which abrogated the changes in Bcl-2 family proteins and cell death produced by doxorubicin. U-0126 blocked the phosphorylation and nuclear translocation of both ERK1/2 and p53, whereas PFT-α blocked only the changes in p53. Doxorubicin and ERK inhibitors produced similar changes in ERK1/2-p53, PARP, and caspase-3 in neonatal rat cultured cardiomyocytes. Thus we conclude that ERK1/2 are functionally linked to p53 and that the ERK1/2-p53 cascade is the upstream signaling pathway responsible for doxorubicin-induced cardiac cell apoptosis. ERKs and p53 may be considered as novel therapeutic targets for the treatment of doxorubicin-induced cardiotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions*
Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.-E., Karandikar, M., Berman, K., & Cobb, M. H. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0428 · Cited by 4,034
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
The DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
PUMA, a Novel Proapoptotic Gene, Is Induced by p53
Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Post-translational modification of p53 in tumorigenesis
Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270
Puma is an essential mediator of p53-dependent and -independent apoptotic pathways
Jeffers, J. R., Parganas, E., Lee, Y., Yang, C., Wang, J., Brennan, J., MacLean, K. H., Han, J., Chittenden, T., Ihle, J. N., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00244-7 · Cited by 879
Anthrazykline in der Krebstherapie: Ein Überblick
Hortobágyi, G. N. (1997) · Drugs · doi:10.2165/00003495-199700544-00003 · Cited by 678
Requirement for ERK Activation in Cisplatin-induced Apoptosis
Wang, X., Martindale, J. L., & Holbrook, N. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004583200 · Cited by 675
Bcl-2-regulated apoptosis: mechanism and therapeutic potential
Adams, J. M., & Cory, S. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.05.004 · Cited by 658
Adriamycin-induced heart failure: mechanisms and modulation
Singal, P., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007094214460 · Cited by 428
The transcriptional targets of p53 in apoptosis control
Yu, J., & Zhang, L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.189 · Cited by 420
ERKs and p38 Kinase Phosphorylate p53 Protein at Serine 15 in Response to UV Radiation
She, Q.-B., Chen, N., & Dong, Z. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001020200 · Cited by 346
Early anthracycline cardiotoxicity
Bristow, M. R., Thompson, P. D., Martin, R. P., Mason, J. W., Billingham, M. E., & Harrison, D. C. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90802-1 · Cited by 334
Doroshow, J. H. (1983) · PubMed · Cited by 329
Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to Cisplatin
Persons, D. L., Yazlovitskaya, E. M., & Pelling, J. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004267200 · Cited by 290
DNA damage is an early event in doxorubicin-induced cardiac myocyte death
L'Ecuyer, T., Sanjeev, S., Thomas, R., Novak, R., Das, L., Campbell, W., & Heide, R. V. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00738.2005 · Cited by 212
Regulation of PUMA-α by p53 in cisplatin-induced renal cell apoptosis
Jiang, M., Wei, Q., Wang, J., Du, Q., Yu, J., Zhang, L., & Dong, Z. (2006) · Oncogene · doi:10.1038/sj.onc.1209440 · Cited by 209
Kang, Y. J., Zhou, Z.-X., Wang, G.-W., Buridi, A., & Klein, J. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.18.13690 · Cited by 207
SPALLAROSSA, P., ALTIERI, P., GARIBALDI, S., GHIGLIOTTI, G., BARISIONE, C., MANCA, V, FABBI, P., BALLESTRERO, A., BRUNELLI, C., & BARSOTTI, A. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.08.009 · Cited by 182
The cardiotoxicity of adriamycin and daunomycin in children
Gilladoga, A. C., Manuel, C., Tan, C. T. C., Wollner, N., Sternberg, S. S., & Murphy, M. L. (1976) · Cancer · doi:10.1002/1097-0142(197602)37:2+<1070::aid-cncr2820370814>3.0.co;2-6 · Cited by 171
Servant, M. J., Giasson, E., & Meloche, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.27.16047 · Cited by 171
Role of ERK activation in cisplatin‐induced apoptosis in OK renal epithelial cells
Kim, Y. K., Kim, H. J., Kwon, C. H., Kim, J. H., Woo, J. S., Jung, J. S., & Kim, J. M. (2005) · Journal of Applied Toxicology · doi:10.1002/jat.1081 · Cited by 167
Pifithrin-α protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice
Liu, X., Chua, C. C., Gao, J., Chen, Z., Landy, C. L. C., Hamdy, R., & Chua, B. H. L. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00759.2003 · Cited by 162
Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice
Shizukuda, Y., Matoba, S., Mian, O. Y., Nguyen, T., & Hwang, P. M. (2005) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-5905-8 · Cited by 148
Stress-induced p53 runs a transcription-independent death program
Erster, S. H., & Moll, U. M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.187 · Cited by 127
Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy
Lou, H., Danelisen, I., & Singal, P. K. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01054.2004 · Cited by 115
The Endothelin Receptor Blocker Bosentan Inhibits Doxorubicin-Induced Cardiomyopathy
Bien, S., Riad, A., Ritter, C. A., Gratz, M., Olshausen, F., Westermann, D., Grube, M., Krieg, T., Ciecholewski, S., Felix, S. B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1344 · Cited by 111
The Involvement of MAPK Signaling Pathways in Determining the Cellular Response to p53 Activation
Brown, L. M., & Benchimol, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507951200 · Cited by 99
Schweyer, S., Soruri, A., Meschter, O., Heintze, A., Zschunke, F., Miosge, N., Thelen, P., Schlott, T., Radzun, H., & Fayyazi, A. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601919 · Cited by 97
Increased p53 protein expression in human failing myocardium
Song, H., Conte, J. V., Foster, A. H., McLaughlin, J. S., & Wei, C. (1999) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(98)00039-4 · Cited by 91
Cui, H., Schroering, A. G., & Ding, H. (2002) · PubMed · Cited by 85
Multiple actions of pifithrin-α on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells
Chua, C. C., Liu, X., Gao, J., Hamdy, R. C., & Chua, B. H. L. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01138.2005 · Cited by 79
Primary Prevention of Coronary Heart Disease: What Has WOSCOPS Told Us and What Questions Remain?
Maher, V. M. G., Sinfuego, J., Chao, P., & Parekh, J. (1997) · Drugs · doi:10.2165/00003495-199754010-00001 · Cited by 74
Nithipongvanitch, R., Ittarat, W., Cole, M. P., Tangpong, J., Clair, D. K. S., & Oberley, T. D. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1632 · Cited by 73
Hempel, G., Flege, S., Würthwein, G., & Boos, J. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-001-0392-4 · Cited by 56
Alkhalaf, M., & Jaffal, S. M. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.04.019 · Cited by 50
Lin, Y., Waldman, B. C., & Waldman, A. S. (2002) · DNA repair · doi:10.1016/s1568-7864(02)00183-0 · Cited by 44
Doxorubicin Degradation in Cardiomyocytes
(2007) · doi:10.1124/jpet.107.122820 · Cited by 40
Okuno, T., Matsuoka, M., Sumizawa, T., & Igisu, H. (2005) · Archives of Toxicology · doi:10.1007/s00204-005-0022-8 · Cited by 35
Suzuki, K., Inageda, K., Nishitai, G., & Matsuoka, M. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.12.028 · Cited by 19
Cited by
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Tacar, O., Sriamornsak, P., & Dass, C. R. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01567.x · Cited by 2,465
ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence
Cagnol, S., & Chambard, J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07366.x · Cited by 1,290
Mitochondria and Mitophagy: The Yin and Yang of Cell Death Control
Kubli, D. A., & Gustafsson, Å. B. (2012) · Circulation Research · doi:10.1161/circresaha.112.265819 · Cited by 796
Rose, B. A., Force, T., & Wang, Y. (2010) · Physiological Reviews · doi:10.1152/physrev.00054.2009 · Cited by 723
Molecular mechanism of doxorubicin-induced cardiomyopathy – An update
Renu, K., V.G., A., P.B., T. P., & Arunachalam, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.043 · Cited by 588
Metadata
- Authors
- Liu, J., Mao, W., Ding, B., & Liang, C.-S.
- Venue
- American Journal of Physiology-Heart and Circulatory Physiology
- Publisher
- American Physiological Society
- Published
- 2008-11
- Volume
- 295
- Issue
- 5
- Pages
- H1956-H1965
- ISSN
- 0363-6135 (ISSN-L)
- 1522-1539
- OpenAlex
- W2168515935
- Cited by
- 255
- References
- 46
- FWCI
- 9.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.